Laurence Gerard

Summary

Country: France

Publications

  1. ncbi Systemic non-Hodgkin lymphoma in HIV-infected patients with effective suppression of HIV replication: persistent occurrence but improved survival
    Laurence Gerard
    Service d Immuno Hématologie Hôpital Saint Louis, AP HP, Paris, France
    J Acquir Immune Defic Syndr 30:478-84. 2002
  2. ncbi Hodgkin's lymphoma as a cause of fever of unknown origin in HIV infection
    L Gerard
    Service d immunopathologie clinique, Hopital Saint Louis, AP HP, Paris, France
    AIDS Patient Care STDS 17:495-9. 2003
  3. ncbi Improved survival in HIV-related Hodgkin's lymphoma since the introduction of highly active antiretroviral therapy
    Laurence Gerard
    Service d Immuno Hématologie and Laboratoire d Anatomopathologie, Hopital Saint Louis, Assistance Publique Hopitaux de Paris, Paris, France
    AIDS 17:81-7. 2003
  4. ncbi Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease
    Laurence Gerard
    Department of Clinical Immunology, Hopital Saint Louis, Assistance Publique Hopitaux de Paris, France
    Blood 119:2228-33. 2012
  5. ncbi Characteristics of non-Hodgkin lymphoma arising in HIV-infected patients with suppressed HIV replication
    Laurence Gerard
    Service d immunopathologie clinique, Hopital Saint Louis, Assistance Publique Hopitaux de Paris, France
    AIDS 23:2301-8. 2009
  6. ncbi B-cell and T-cell phenotypes in CVID patients correlate with the clinical phenotype of the disease
    Gael Mouillot
    Immunology Laboratory, INSERM UMR S945, CIB Pitié Salpêtrière, Assistance Publique Hopitaux de Paris, Paris, France
    J Clin Immunol 30:746-55. 2010
  7. ncbi Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial
    Laurence Gerard
    Department of Clinical Immunology, Laboratory of Virology, Paris VII University, Paris, France
    J Clin Oncol 25:3350-6. 2007
  8. ncbi Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study
    Lionel Galicier
    Departments of Clinical Immunology, Hopital St Louis, Assistance Publique Hopitaux de Paris, Paris, France
    Blood 110:2846-54. 2007
  9. ncbi Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial
    Christophe Piketty
    Department of Immunology, Hôpital Georges Pompidou, Assistance Publique Hopitaux de Paris, Paris, France
    Antivir Ther 11:213-21. 2006
  10. ncbi Parental consanguinity is associated with a severe phenotype in common variable immunodeficiency
    Claire Rivoisy
    Department of Clinical Immunology, Hopital Saint Louis, Assistance Publique Hôpitaux de Paris and Université Paris Diderot, Sorbonne Paris Cité, EA3963, Paris, France
    J Clin Immunol 32:98-105. 2012

Collaborators

Detail Information

Publications18

  1. ncbi Systemic non-Hodgkin lymphoma in HIV-infected patients with effective suppression of HIV replication: persistent occurrence but improved survival
    Laurence Gerard
    Service d Immuno Hématologie Hôpital Saint Louis, AP HP, Paris, France
    J Acquir Immune Defic Syndr 30:478-84. 2002
    ..Improvement in the overall survival rate in the post-HAART period was associated with more intensive chemotherapy regimens, increased complete remission rate, and a likely benefit of continuation or introduction of HAART...
  2. ncbi Hodgkin's lymphoma as a cause of fever of unknown origin in HIV infection
    L Gerard
    Service d immunopathologie clinique, Hopital Saint Louis, AP HP, Paris, France
    AIDS Patient Care STDS 17:495-9. 2003
    ....
  3. ncbi Improved survival in HIV-related Hodgkin's lymphoma since the introduction of highly active antiretroviral therapy
    Laurence Gerard
    Service d Immuno Hématologie and Laboratoire d Anatomopathologie, Hopital Saint Louis, Assistance Publique Hopitaux de Paris, Paris, France
    AIDS 17:81-7. 2003
    ..To evaluate the evolving characteristics of HIV-related Hodgkin's lymphoma (HL) and survival of affected patients since the introduction of highly active antiretroviral therapy (HAART)...
  4. ncbi Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease
    Laurence Gerard
    Department of Clinical Immunology, Hopital Saint Louis, Assistance Publique Hopitaux de Paris, France
    Blood 119:2228-33. 2012
    ..Rituximab was associated with an 11-fold lower risk of developing lymphoma. KS exacerbation was the most challenging adverse event after rituximab therapy...
  5. ncbi Characteristics of non-Hodgkin lymphoma arising in HIV-infected patients with suppressed HIV replication
    Laurence Gerard
    Service d immunopathologie clinique, Hopital Saint Louis, Assistance Publique Hopitaux de Paris, France
    AIDS 23:2301-8. 2009
    ..Despite effective treatment of HIV infection, some patients still develop non-Hodgkin lymphoma (NHL). We analysed patients with HIV-associated NHL and undetectable plasma HIV-RNA, according to the duration of HIV suppression...
  6. ncbi B-cell and T-cell phenotypes in CVID patients correlate with the clinical phenotype of the disease
    Gael Mouillot
    Immunology Laboratory, INSERM UMR S945, CIB Pitié Salpêtrière, Assistance Publique Hopitaux de Paris, Paris, France
    J Clin Immunol 30:746-55. 2010
    ..Common variable immunodeficiency (CVID) is a heterogeneous disorder characterized by recurrent infections and defective immunoglobulin production...
  7. ncbi Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial
    Laurence Gerard
    Department of Clinical Immunology, Laboratory of Virology, Paris VII University, Paris, France
    J Clin Oncol 25:3350-6. 2007
    ..Single-agent chemotherapy is usually effective in HIV-associated multicentric Castleman's disease (MCD). However, in most patients, chemotherapy cannot be discontinued...
  8. ncbi Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study
    Lionel Galicier
    Departments of Clinical Immunology, Hopital St Louis, Assistance Publique Hopitaux de Paris, Paris, France
    Blood 110:2846-54. 2007
    ..We conclude that LMB86 regimen is highly effective in advanced HIV-related BL and should be proposed for patients with CD4 count higher than 200 x 10(6)/L or ECOG of 2 or less...
  9. ncbi Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial
    Christophe Piketty
    Department of Immunology, Hôpital Georges Pompidou, Assistance Publique Hopitaux de Paris, Paris, France
    Antivir Ther 11:213-21. 2006
    ..Ritonavir (RTV)-boosted atazanavir (ATV) and tenofovir disoproxil fumarate (TDF-DF) are promising in highly experienced patients because of their pharmacokinetic profile, activity, safety and resistance properties...
  10. ncbi Parental consanguinity is associated with a severe phenotype in common variable immunodeficiency
    Claire Rivoisy
    Department of Clinical Immunology, Hopital Saint Louis, Assistance Publique Hôpitaux de Paris and Université Paris Diderot, Sorbonne Paris Cité, EA3963, Paris, France
    J Clin Immunol 32:98-105. 2012
    ..Systematic investigation for parental consanguinity in patients with CVID provides useful information for specific clinical care and genetic screening...
  11. ncbi Immunoglobulin dosage and switch from intravenous to subcutaneous immunoglobulin replacement therapy in patients with primary hypogammaglobulinemia: decreasing dosage does not alter serum IgG levels
    Sylvain Thepot
    Departement d Immunologie, Hopital Saint Louis, Assistance Publique Hopitaux de Paris, 1 avenue Claude Vellefaux, 75010 Paris, France
    J Clin Immunol 30:602-6. 2010
    ..The impact of reducing immunoglobulin dosage while switching from intravenous to subcutaneous replacement therapy was evaluated...
  12. ncbi Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS
    Emmanuelle Boulanger
    Department of Clinical Immunology, Hopital Saint Louis, Assistance Publique Hopitaux de Paris, 1 avenue Claude Vellefaux, 75 475 Paris Cedex 10, France
    J Clin Oncol 23:4372-80. 2005
    ..The prognosis is poor, with reported median survival time shorter than 6 months. To date, no prognostic factor has been identified in this subset of lymphoma...
  13. ncbi Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1
    Odile Launay
    Service de Maladies Infectieuses et Tropicales, Hopital Bichat Claude Bernard, Paris, France
    Clin Infect Dis 35:1096-105. 2002
    ..These results do not support the use of a 3-class regimen that includes Nvp for patients with no or limited exposure to nucleoside analogues...
  14. ncbi Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients
    Anne Marie Taburet
    Clinical Pharmacy, Hospital Bicêtre Assistance Publique Hôpitaux de Paris, 78 rue du General Leclerc, 94270 Kremlin Bicetre, France
    Antimicrob Agents Chemother 48:2091-6. 2004
    ..The median decreases in the HIV RNA loads at week 2 and week 6 were 0.1 and 0.2 log copies/ml, respectively. In summary, our data are consistent with the existence of a significant interaction between atazanavir and tenofovir DF...
  15. ncbi Anal carcinoma in HIV-infected patients in the era of antiretroviral therapy: a comparative study
    Nicolas Munoz-Bongrand
    Department of Digestive and Endocrine Surgery, Hopital Saint Louis, Paris, France
    Dis Colon Rectum 54:729-35. 2011
    ..Before the introduction of highly active antiretroviral therapy, prognosis of anal squamous-cell carcinoma was worse when patients were infected with HIV. Since then, contradictory results have been reported...
  16. ncbi Late-onset combined immune deficiency: a subset of common variable immunodeficiency with severe T cell defect
    Marion Malphettes
    Departement d Immunologie, Hopital Saint Louis, Assistance Publique Hopitaux de Paris, Paris, France
    Clin Infect Dis 49:1329-38. 2009
    ..Common variable immunodeficiency (CVID) is a primary immune deficiency defined by defective antibody production. In most series, a small proportion of patients present with opportunistic infections (OIs)...
  17. ncbi Infections in 252 patients with common variable immunodeficiency
    Eric Oksenhendler
    Department of Clinical Immunology, Hopital Saint Louis, Paris, France
    Clin Infect Dis 46:1547-54. 2008
    ..Common variable immunodeficiency is characterized by recurrent infections and defective immunoglobulin production...
  18. ncbi Contribution of cellular HIV-1 DNA quantification to the efficacy analysis of antiretroviral therapy: a randomized comparison of 2 regimens, including 3 drugs from 2 or 3 classes (TRIANON, ANRS 081)
    Laurence Morand-Joubert
    Saint Antoine Hospital, AP HP, Universite Paris VI, Paris, France
    J Acquir Immune Defic Syndr 38:268-76. 2005
    ..In conclusion, the changes under therapy in cellular HIV-1 DNA level, which were mostly coincident to those of plasma HIV-1 RNA, did not add significant information to the comparison of the viral efficacy of the 2 studied regimens...